Erdoğan Şeyran

Dr. Erdoğan Şeyran

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2025 in Healthcare
Verified
Journal Article
Open access
PDF file
İDİbrahim Doğan
İbrahim Doğan
Mehmet Kadir BartınMehmet Kadir Bartın
Mehmet Kadir Bartın
ESEzgi Sonmez
Ezgi Sonmez
EŞErdoğan Şeyran
Erdoğan Şeyran
HBHALİL ALPER BOZKURT
HALİL ALPER BOZKURT
SCSebahattin Celik
Sebahattin Celik
Background: Multidisciplinary Tumor Councils (MDTs) are vital platforms that provide tailored treatment plans for cancer patients by combining expertise from various medical disciplines. Recently, Artificial Intelligence (AI) tools have been investigated as decision-support systems within these councils. Methods: In this prospective study, the compatibility of AI (ChatGPT-4.0) with MDT decisions was evaluated in 100 cancer patients presented to the tumor council between November 2024 and January 2025. AI-generated treatment recommendations based on anonymized, detailed clinical summaries were compared with real-time MDT decisions. Cohen’s Kappa and Spearman correlation tests were used for statistical analysis. Results: Neoadjuvant treatment (45%) and surgery (36%) were the most frequent MDT decisions. AI recommended surgery (39%) and neoadjuvant treatment (37%) most frequently. A high concordance rate of 76.4% was observed between AI and MDT decisions (κ = 0.764 [95% CI; 0.658–0.870] p < 0.001, ρ = 0.810 [95% CI; 0.729–0.868], p < 0.001). Most inconsistencies arose in cases requiring individualized decisions, indicating AI’s current limitations in incorporating contextual clinical judgment. Conclusion: AI demonstrates substantial agreement with MDT decisions, particularly in cases adhering to standardized oncological guidelines. However, for AI integration into clinical workflows, it must evolve to interpret real-time patient data and function transparently within ethical and legal frameworks.

8 August 2026 in Journal of Current Hematology & Oncology Research
Verified
Journal Article
Closed access
EŞErdoğan Şeyran
Erdoğan Şeyran
AGAzer Gökmen
Azer Gökmen
Aims: Identifying factors affecting the prognosis of gastric cancer is clinically important. Although ABO and Rh blood groups have been suggested to have a prognostic role in various malignancies, their impact in gastric cancer remains unclear. This study aimed to evaluate the association of ABO and Rh blood groups with clinicopathological characteristics and overall survival in patients with gastric adenocarcinoma. Methods: In this retrospective single-center study, 320 patients diagnosed with gastric adenocarcinoma were included. Demographic and clinical data were obtained from electronic medical records. Overall survival was analyzed using the Kaplan–Meier method, and differences between groups were compared using the log-rank test. Cox regression analysis was performed to identify prognostic factors. Results: The mean age of the patients was 70.2 ± 9.5 years, and 68.4% were male. Among clinicopathological characteristics, only surgical treatment showed a statistically significant association with ABO blood groups (p=0.047). The median overall survival was 15.8 months. No statistically significant association was found between ABO blood groups (p=0.223) or Rh factor (p=0.850) and overall survival. The presence of metastasis was significantly associated with overall survival (p<0.001). A statistically significant difference in overall survival was observed according to primary surgical treatment status (p<0.001). In multivariate analysis, only surgical treatment was identified as an independent prognostic factor (HR: 0.58; 95% CI: 0.40–0.85; p=0.005). Conclusion: ABO and Rh blood groups were not found to have a significant prognostic impact on overall survival in patients with gastric adenocarcinoma. In contrast, clinical factors such as metastasis and surgical treatment were identified as key determinants of survival. These findings suggest that prognosis in gastric cancer is more closely related to disease extent and treatment strategies rather than blood group characteristics.

30 July 2026 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
EŞErdoğan Şeyran
Erdoğan Şeyran
AGAzer Gökmen
Azer Gökmen
EHEmre Hafızoğlu
Emre Hafızoğlu
Background: The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) classification remains the cornerstone of prognostic assessment in metastatic renal cell carcinoma (mRCC). However, whether metastatic burden and host-related inflammatory and nutritional biomarkers meaningfully improve prognostic discrimination beyond IMDC has not been fully established. This study aimed to evaluate whether expanded prognostic models incorporating metastatic burden, bone metastasis, neutrophil-to-lymphocyte ratio (NLR), albumin, and lactate dehydrogenase (LDH) improve survival discrimination beyond IMDC in a real-world mRCC cohort. Methods: We retrospectively evaluated 104 patients with mRCC treated at a single tertiary oncology center. Overall survival (OS), defined from the diagnosis of metastatic disease, was analyzed using Kaplan–Meier analysis and Cox proportional hazards regression models. Sequential multivariable Cox models were constructed by progressively adding metastatic burden, NLR, albumin, and LDH to the IMDC model. An alternative model incorporating bone metastasis status was also evaluated. Model performance was assessed using Harrell’s concordance index (C-index), −2 Log Likelihood statistics, and likelihood-ratio (LR) tests. Results: The cohort consisted predominantly of male patients (69.2%), with a median age of 60.3 years at metastatic diagnosis. According to IMDC classification, 24.0% of patients were favorable risk, 51.9% intermediate risk, and 24.0% poor risk. Median OS was 85.36 months in the favorable-risk group, 38.11 months in the intermediate-risk group, and 18.27 months in the poor-risk group (log-rank p<0.001). Elevated NLR was associated with significantly shorter OS in Kaplan–Meier analysis and with increased mortality in univariate Cox analysis (HR = 1.86, 95% CI 1.09–3.20, p=0.024), while higher serum albumin was associated with improved OS in univariate analysis (HR = 0.53, 95% CI 0.30–0.91, p=0.021). The fully expanded model demonstrated the highest discrimination (Harrell’s C-index 0.720), compared with 0.664 for the IMDC-only model. However, none of the sequential additions beyond IMDC significantly improved model performance according to likelihood-ratio testing, and metastatic burden, bone metastasis, NLR, albumin, and LDH did not retain independent prognostic significance after multivariable adjustment. Conclusions: In this real-world mRCC cohort, IMDC remained the dominant determinant of survival outcomes. Although expanded prognostic models incorporating metastatic burden and host-related biomarkers provided modest numerical improvements in model discrimination, they did not confer statistically significant incremental prognostic value beyond IMDC. These findings support the continued central role of IMDC for prognostic stratification in routine clinical practice.

24 August 2026 in Current Oncology
Verified
Journal Article
Open access
PDF file
EŞErdoğan Şeyran
Erdoğan Şeyran
EHEmre Hafızoğlu
Emre Hafızoğlu
Background: Prognostic assessment after neoadjuvant chemotherapy and curative gastrectomy remains challenging in patients with gastric adenocarcinoma because postoperative outcomes are influenced by both pretreatment disease burden and pathological response. We aimed to develop and internally validate a clinicopathological prognostic model and a simple postoperative risk classification for predicting disease-free survival (DFS). Methods: This single-center retrospective cohort study included patients with gastric adenocarcinoma who underwent neoadjuvant chemotherapy followed by curative gastrectomy. Pretreatment clinicopathological variables, Becker tumor regression grade (TRG), and serum tumor markers were evaluated. Logistic regression was used to identify predictors of favorable pathological response, whereas Cox proportional hazards regression was performed to identify independent prognostic factors for disease-free survival (DFS). Sequential prognostic models were developed and internally validated using 1000 bootstrap resamples. A simplified postoperative clinicopathological risk classification based on pretreatment clinical N stage and Becker tumor regression grade was additionally developed to facilitate clinical interpretation and postoperative risk stratification. Results: A total of 109 patients were included. Favorable pathological response (Becker TRG1–2) was achieved in 68 patients (62.4%), whereas 41 patients (37.6%) had minimal or no pathological response (TRG3). In multivariable logistic regression analysis, pretreatment clinical T stage (cT4 vs. cT1–3) and clinical N stage (cN2–3 vs. cN0–1) were independently associated with a lower likelihood of achieving a favorable pathological response. For disease-free survival, pretreatment clinical N stage, Becker tumor regression grade, and log10-transformed CA19-9 remained independent prognostic factors in the multivariable Cox model. Sequential model development demonstrated progressive improvement in model discrimination, with the optimism-corrected Harrell’s C-index increasing from 0.697 for the clinical N stage model to 0.770 for the final model incorporating clinical N stage, Becker tumor regression grade, and CA19-9. Bootstrap internal validation demonstrated minimal optimism, and calibration analysis showed good agreement between predicted and observed disease-free survival. A simple postoperative clinicopathological risk classification successfully stratified patients into distinct prognostic groups. Conclusions: A clinicopathological prognostic model integrating pretreatment clinical N stage, Becker tumor regression grade, and serum CA19-9 demonstrated improved prognostic discrimination for disease-free survival compared with clinical N stage alone. The derived postoperative risk classification may provide a simple framework for postoperative risk stratification and could assist in individualizing postoperative surveillance. External validation is warranted before routine clinical implementation.

20 February 2026 in Journal of Medicine and Palliative Care
Verified
Journal Article
Open access
MDMehmet Salim Demir
Mehmet Salim Demir
GAGözde Ağdaş
Gözde Ağdaş
EŞErdoğan Şeyran
Erdoğan Şeyran
GGGürkan Güner
Gürkan Güner
Aims: Glioblastoma (GBM) is the most aggressive primary brain tumor in adults, with limited survival despite multimodal treatment. This retrospective study evaluated the prognostic impact molecular markers and clinical factors on survival outcomes in a real world GBM cohort. Methods: We conducted a retrospective analysis of 60 patients diagnosed with GBM between 2020 and 2023. Clinical, radiological, surgical, and molecular data were retrospectively collected. Overall survival (OS) and progression-free survival (PFS) were analyzed using Kaplan-Meier curves, with compared with log-rank test. Multivariable Cox regression analysis was performed to identify independent prognostic factors. Results: Median OS and PFS for the entire cohort were 16.5 and 9.8 months, respectively. Molecular markers were the strongest prognostic factors: IDH-mutant and MGMT-methylated tumors showed significantly prolonged OS and PFS compared to their wild-type/unmethylated counterparts (p

29 September 2026 in Bagcilar Medical Bulletin
Verified
Journal Article
Open access
PDF file
EŞErdoğan Şeyran
Erdoğan Şeyran
AGAzer Gökmen
Azer Gökmen
Association of Tumor Distribution Pattern with Stage at Diagnosis and Presentation Pattern in Patients with Invasive Breast Cancer - Bagcilar Medical Bulletin